<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31210678</article-id><article-id pub-id-type="pmc">6560374</article-id><article-id pub-id-type="publisher-id">BLT.18.228577</article-id><article-id pub-id-type="doi">10.2471/BLT.18.228577</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">D&#x000e9;clin de la tuberculose dans les populations touch&#x000e9;es par le VIH: une &#x000e9;tude r&#x000e9;trospective dans 12&#x000a0;pays de la R&#x000e9;gion africaine de l&#x02019;OMS</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Descenso de la tuberculosis en las poblaciones afectadas por el VIH: un estudio retrospectivo de 12 pa&#x000ed;ses de la regi&#x000f3;n africana de la OMS</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00644;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629;: &#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x00628;&#x00623;&#x0062b;&#x00631; &#x00631;&#x0062c;&#x00639;&#x0064a; &#x00641;&#x0064a; 12 &#x00628;&#x00644;&#x0062f;&#x00627;&#x0064b; &#x00623;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00627;&#x0064b; &#x00641;&#x0064a;&#x00627;&#x00644;&#x00645;&#x00646;&#x00637;&#x00642;&#x00629; &#x00627;&#x00644;&#x00623;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; ( <bold>WHO </bold>) </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x053d7;&#x0827e;&#x06ecb;&#x075c5;&#x06bd2;&#x05f71;&#x054cd;&#x07684;&#x07ed3;&#x06838;&#x075c5;&#x060a3;&#x08005;&#x04eba;&#x06570;&#x0964d;&#x04f4e;:&#x05bf9;&#x04e16;&#x0536b;&#x07ec4;&#x07ec7;&#x0975e;&#x06d32;&#x0533a;&#x057df;&#x000a0;12&#x000a0;&#x056fd;&#x07684;&#x056de;&#x0987e;&#x06027;&#x07814;&#x07a76;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">C&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00441;&#x00442;&#x00440;&#x00430;&#x00434;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00412;&#x00418;&#x00427;: &#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00432; 12&#x000a0;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x00410;&#x00444;&#x00440;&#x00438;&#x0043a;&#x00430;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430; &#x00412;&#x0041e;&#x00417;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Christopher Dye &#x00026; Brian G Williams</alt-title><alt-title alt-title-type="title-running-head">Tuberculosis in populations affected by HIV</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dye</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Brian G</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label>Department of Zoology and All Souls College, University of Oxford, High Street, <addr-line>Oxford OX1 4AL</addr-line>, <country>England</country>.</aff><aff id="aff2"><label>b</label>South African Centre for Epidemiological Modelling and Analysis (SACEMA), <institution>Stellenbosch University</institution>, <addr-line>Stellenbosch</addr-line>, <country>South Africa</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Christopher Dye (email: <email xlink:href="chrisdye56@gmail.com">chrisdye56@gmail.com</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2019</year></pub-date><volume>97</volume><issue>6</issue><fpage>405</fpage><lpage>414</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2018</year></date><date date-type="rev-recd"><day>17</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2019</year></date></history><permissions><copyright-statement>(c) 2019 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To investigate which of the World Health Organization recommended methods for tuberculosis control have had the greatest effect on case incidence in 12 countries in the World Health Organization (WHO) African Region that carry high burdens of tuberculosis linked to human immunodeficiency virus (HIV) infection.</p></sec><sec><title>Methods</title><p>We obtained epidemiological surveillance, survey and treatment data on HIV and tuberculosis for the years 2003 to 2016. We used statistical models to examine the effects of antiretroviral therapy (ART) and isoniazid preventive therapy in reducing the incidence of tuberculosis among people living with HIV. We also investigated the role of tuberculosis case detection and treatment in preventing <italic>Mycobacterium tuberculosis</italic> transmission and consequently reducing tuberculosis incidence.</p></sec><sec><title>Findings</title><p>Between 2003 and 2016, ART provision was associated with the decline of tuberculosis in each country, and with differences in tuberculosis decline between countries. Inferring that ART was a cause of tuberculosis decline, ART prevented 1.88 million (95% confidence interval, CI: 1.65 to 2.11) tuberculosis cases in people living with HIV, or 15.7% (95% CI: 13.8 to 17.6) of the 11.96 million HIV-positive tuberculosis cases expected. Population coverage of isoniazid preventive therapy was too low (average 1.0% of persons eligible) to have a major effect on tuberculosis decline, and improvements in tuberculosis detection and treatment were either weakly associated or not significantly associated with tuberculosis decline.</p></sec><sec><title>Conclusion</title><p>ART provision is associated with tuberculosis decline in these 12 countries. ART should remain central to tuberculosis control where rates of tuberculosis&#x02013;HIV coinfection are high, but renewed efforts to treat tuberculosis are needed.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Rechercher quelle m&#x000e9;thode recommand&#x000e9;e par l'Organisation mondiale de la Sant&#x000e9; pour lutter contre la tuberculose a eu le plus gros effet sur l'incidence de la maladie dans 12&#x000a0;pays de la R&#x000e9;gion africaine de l&#x02019;Organisation mondiale de la Sant&#x000e9; (OMS) fortement touch&#x000e9;s par la tuberculose en lien avec le virus de l'immunod&#x000e9;ficience humaine (VIH).</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous nous sommes procur&#x000e9; des donn&#x000e9;es &#x000e9;pid&#x000e9;miologiques de surveillance, d'enqu&#x000ea;te et de traitement concernant le VIH et la tuberculose pour les ann&#x000e9;es 2003 &#x000e0; 2016. Nous avons utilis&#x000e9; des mod&#x000e8;les statistiques pour examiner les effets des traitements antir&#x000e9;troviraux (TAR) et des traitements pr&#x000e9;ventifs par isoniazide sur la r&#x000e9;duction de l'incidence de la tuberculose chez les personnes atteintes du VIH. Nous avons &#x000e9;galement analys&#x000e9; le r&#x000f4;le que jouent le d&#x000e9;pistage et le traitement de la tuberculose dans la pr&#x000e9;vention de la transmission de <italic>Mycobacterium tuberculosis</italic> et donc dans la r&#x000e9;duction de l'incidence de la maladie.</p></sec><sec><title>R&#x000e9;sultats</title><p>Entre 2003 et 2016, la prise de TAR a &#x000e9;t&#x000e9; associ&#x000e9;e &#x000e0; un d&#x000e9;clin de la tuberculose dans tous les pays, avec des diff&#x000e9;rences dans le d&#x000e9;clin de la maladie selon les pays. En d&#x000e9;duisant que les TAR &#x000e9;taient une des raisons du d&#x000e9;clin de la tuberculose, ceux-ci ont emp&#x000ea;ch&#x000e9; 1,88&#x000a0;million (intervalle de confiance de 95%, IC: 1,65 &#x000e0; 2,11) de cas de tuberculose chez les personnes atteintes du VIH, soit 15,7% (IC 95%: 13,8 &#x000e0; 17,6) des 11,96&#x000a0;millions de cas de tuberculose attendus chez des patients s&#x000e9;ropositifs au VIH. La couverture des traitements pr&#x000e9;ventifs par isoniazide dans la population &#x000e9;tait trop faible (en moyenne 1,0% des personnes &#x000e9;ligibles) pour avoir un effet notable sur le d&#x000e9;clin de la tuberculose, et les am&#x000e9;liorations apport&#x000e9;es &#x000e0; la d&#x000e9;tection et au traitement de la maladie &#x000e9;taient associ&#x000e9;es faiblement ou de mani&#x000e8;re non significative au d&#x000e9;clin de la tuberculose.</p></sec><sec><title>Conclusion</title><p>Les TAR sont associ&#x000e9;s au d&#x000e9;clin de la tuberculose dans ces 12&#x000a0;pays. Les TAR devraient rester au c&#x00153;ur de la lutte contre la tuberculose lorsque le taux de co-infection tuberculose/VIH est &#x000e9;lev&#x000e9;, mais un regain d'efforts est &#x000e9;galement n&#x000e9;cessaire pour combattre la tuberculose.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Investigar cu&#x000e1;les de los m&#x000e9;todos recomendados por la Organizaci&#x000f3;n Mundial de la Salud para el control de la tuberculosis han tenido el mayor efecto en la incidencia de casos en 12 pa&#x000ed;ses de la regi&#x000f3;n africana de la Organizaci&#x000f3;n Mundial de la Salud (OMS) que soportan altas cargas de tuberculosis relacionadas con la infecci&#x000f3;n por el virus de la inmunodeficiencia humana (VIH).</p></sec><sec><title>M&#x000e9;todos</title><p>Se obtuvieron datos de vigilancia epidemiol&#x000f3;gica, encuestas y tratamientos sobre el VIH y la tuberculosis para los a&#x000f1;os 2003 a 2016. Se utilizaron modelos estad&#x000ed;sticos para examinar los efectos de la terapia antirretroviral (TAR) y la terapia preventiva con isoniazida en la reducci&#x000f3;n de la incidencia de la tuberculosis entre las personas que viven con el VIH. Tambi&#x000e9;n se investig&#x000f3; el papel de la detecci&#x000f3;n y el tratamiento de casos de tuberculosis en la prevenci&#x000f3;n de la transmisi&#x000f3;n de <italic>Mycobacterium tuberculosis</italic> y, en consecuencia, en la reducci&#x000f3;n de la incidencia de la tuberculosis.</p></sec><sec><title>Resultados</title><p>Entre 2003 y 2016, la provisi&#x000f3;n de TAR se asoci&#x000f3; con la disminuci&#x000f3;n de la tuberculosis en todos los pa&#x000ed;ses y con diferencias en el descenso de la tuberculosis entre los pa&#x000ed;ses. Deduciendo que la TAR era una causa del descenso de la tuberculosis, la TAR previno 1,88 millones (intervalo de confianza, IC del 95&#x000a0;%: 1,65 a 2,11) de casos de tuberculosis en personas que viven con el VIH, o el 15,7&#x000a0;% (IC del 95&#x000a0;%: 13,8 a 17,6) de los 11,96 millones de casos de tuberculosis seropositiva previstos. La cobertura de la poblaci&#x000f3;n del tratamiento preventivo con isoniazida era demasiado baja (una media del 1,0&#x000a0;% de las personas admisibles) como para tener un efecto importante sobre el descenso de la tuberculosis y las mejoras en la detecci&#x000f3;n y el tratamiento de la tuberculosis se asociaron d&#x000e9;bilmente o no se asociaron de forma significativa con el descenso de la tuberculosis.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La provisi&#x000f3;n de la terapia antirretroviral est&#x000e1; asociada con el descenso de la tuberculosis en estos 12 pa&#x000ed;ses. La TAR debe seguir siendo fundamental para el control de la tuberculosis, donde las tasas de coinfecci&#x000f3;n por tuberculosis y VIH son elevadas, pero es necesario redoblar los esfuerzos para tratar la tuberculosis.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641; &#x00623;&#x0064a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00637;&#x00631;&#x00642; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x00623;&#x00648;&#x00635;&#x0062a; &#x00628;&#x00647;&#x00627; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00643;&#x00627;&#x00641;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00633;&#x00644;&#x0060c; &#x00643;&#x00627;&#x00646; &#x00644;&#x0062f;&#x0064a;&#x00647;&#x00627; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00643;&#x00628;&#x00631; &#x00639;&#x00644;&#x00649; &#x0062d;&#x0062f;&#x00648;&#x0062b; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00641;&#x0064a; 12 &#x00628;&#x00644;&#x0062f;&#x00627;&#x0064b; &#x00625;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00627;&#x0064b; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x00646;&#x00637;&#x00642;&#x00629; &#x00627;&#x00644;&#x00623;&#x00641;&#x00631;&#x0064a;&#x00642;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629;(WHO) &#x00645;&#x00646; &#x0062a;&#x00644;&#x00643; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x0062a;&#x0062d;&#x00645;&#x00644; &#x00623;&#x00639;&#x00628;&#x00627;&#x00621;&#x0064b; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629; <bold> (HIV) </bold>&#x00644;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00625;&#x00646;&#x00633;&#x00627;&#x00646; <bold>. </bold></p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00644;&#x00642;&#x0062f; &#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00639;&#x00646; &#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00648;&#x00628;&#x00627;&#x00626;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062d; &#x00648;&#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x00633;&#x00644; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00627;&#x00644;&#x00623;&#x00639;&#x00648;&#x00627;&#x00645; &#x00645;&#x00646; 2003 &#x00625;&#x00644;&#x00649; 2016. &#x00643;&#x00645;&#x00627; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00639;&#x00627;&#x00646;&#x00629; &#x00628;&#x00646;&#x00645;&#x00627;&#x00630;&#x0062c; &#x00625;&#x0062d;&#x00635;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x00622;&#x0062b;&#x00627;&#x00631; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; ( <bold>ART </bold>) &#x00648;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00623;&#x0064a;&#x00632;&#x00648;&#x00646;&#x0064a;&#x00627;&#x00632;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x00626;&#x0064a; &#x00644;&#x00644;&#x0062d;&#x0062f; &#x00645;&#x00646; &#x0062d;&#x0062f;&#x00648;&#x0062b; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00644; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629;. &#x00642;&#x00645;&#x00646;&#x00627; &#x00643;&#x00630;&#x00644;&#x00643; &#x00628;&#x00627;&#x00644;&#x00628;&#x0062d;&#x0062b; &#x00641;&#x0064a; &#x0062f;&#x00648;&#x00631; &#x00627;&#x00644;&#x00643;&#x00634;&#x00641; &#x00639;&#x00646; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00644; &#x00648;&#x00639;&#x00644;&#x00627;&#x0062c;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00645;&#x00646;&#x00639; &#x00627;&#x00646;&#x0062a;&#x00642;&#x00627;&#x00644; &#x00627;&#x00644;&#x00633;&#x00644;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 2003 &#x00648;2016&#x0060c; &#x00627;&#x00631;&#x0062a;&#x00628;&#x00637; &#x0062a;&#x00648;&#x00641;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; &#x00628;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00641;&#x0064a; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00641;&#x0064a; &#x00643;&#x00644; &#x00628;&#x00644;&#x0062f;&#x0060c; &#x00645;&#x00639; &#x00648;&#x0062c;&#x00648;&#x0062f; &#x00627;&#x0062e;&#x0062a;&#x00644;&#x00627;&#x00641;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00644;&#x0062f;&#x00627;&#x00646;. &#x00648;&#x00628;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; &#x00623;&#x00646; &#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; &#x00642;&#x0062f; &#x00623;&#x0062f;&#x0062a; &#x00625;&#x00644;&#x00649; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00645;&#x00639;&#x0062f;&#x00644; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644;&#x0060c; &#x00641;&#x00642;&#x0062f; &#x00623;&#x0062f;&#x0062a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; 1.88 &#x00645;&#x00644;&#x0064a;&#x00648;&#x00646; (&#x00641;&#x00627;&#x00635;&#x00644; &#x00627;&#x00644;&#x0062b;&#x00642;&#x00629; <styled-content style-type="direction" style="direction:ltr;">95%</styled-content>: &#x00645;&#x00646; 1.65 &#x00625;&#x00644;&#x00649; 2.11) &#x0062d;&#x00627;&#x00644;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629;&#x0060c; &#x00623;&#x00648; <styled-content style-type="direction" style="direction:ltr;">15.7% </styled-content>(&#x00641;&#x00627;&#x00635;&#x00644; &#x0062b;&#x00642;&#x00629; <styled-content style-type="direction" style="direction:ltr;">95%</styled-content>: 13.8 &#x00625;&#x00644;&#x00649; 17.6) &#x00645;&#x00646; 11.96 &#x00645;&#x00644;&#x0064a;&#x00648;&#x00646; &#x0062d;&#x00627;&#x00644;&#x00629; &#x00644;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00648;&#x00642;&#x00639;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00644;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0064a;&#x00639;&#x00627;&#x00646;&#x00648;&#x00646; &#x00645;&#x00646; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629;. &#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x00637;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00623;&#x0064a;&#x00632;&#x00648;&#x00646;&#x0064a;&#x00627;&#x00632;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x00626;&#x0064a; &#x00645;&#x00646;&#x0062e;&#x00641;&#x00636;&#x00629; &#x00644;&#x00644;&#x0063a;&#x00627;&#x0064a;&#x00629; (&#x00628;&#x00645;&#x0062a;&#x00648;&#x00633;&#x00637; 1.0&#x0066a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00645;&#x00624;&#x00647;&#x00644;&#x0064a;&#x00646;) &#x00644;&#x0064a;&#x00643;&#x00648;&#x00646; &#x00644;&#x00647;&#x00627; &#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00639;&#x00644;&#x00649; &#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644;&#x0060c; &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00633;&#x0064a;&#x00646;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00648;&#x00639;&#x00644;&#x00627;&#x0062c;&#x00647; &#x00625;&#x00645;&#x00627; &#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00634;&#x00643;&#x00644; &#x00636;&#x00639;&#x0064a;&#x00641; &#x00623;&#x00648; &#x0063a;&#x0064a;&#x00631; &#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00634;&#x00643;&#x00644; &#x00645;&#x00644;&#x00645;&#x00648;&#x00633; &#x00628;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00627;&#x00631;&#x0062a;&#x00628;&#x00637; &#x0062a;&#x00648;&#x00641;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; &#x00628;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00641;&#x0064a; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00641;&#x0064a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x00627;&#x00644;&#x00625;&#x0062b;&#x00646;&#x00627; &#x00639;&#x00634;&#x00631;. &#x0064a;&#x0062c;&#x00628; &#x00623;&#x00646; &#x0064a;&#x00638;&#x00644; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; &#x00643;&#x0062d;&#x0062c;&#x00631; &#x00644;&#x00644;&#x00632;&#x00627;&#x00648;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00645;&#x00643;&#x00627;&#x00641;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00633;&#x00644; &#x0062d;&#x0064a;&#x0062b; &#x0062a;&#x00643;&#x00648;&#x00646; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00644; &#x00648;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00646;&#x00642;&#x00635; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a;&#x00629; &#x00645;&#x00639;&#x00627;&#x0064b; &#x00645;&#x00631;&#x0062a;&#x00641;&#x00639;&#x00629;&#x0060c; &#x00625;&#x00644;&#x00627; &#x00623;&#x00646; &#x00647;&#x00646;&#x00627;&#x00643; &#x0062d;&#x00627;&#x0062c;&#x00629; &#x00644;&#x0062c;&#x00647;&#x00648;&#x0062f; &#x00645;&#x0062a;&#x0062c;&#x0062f;&#x0062f;&#x00629; &#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00645;&#x00631;&#x00636; &#x00648;&#x00639;&#x0062f;&#x00648;&#x00649; &#x00627;&#x00644;&#x00633;&#x00644; <bold>. </bold></p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x07814;&#x07a76;&#x054ea;&#x04e9b;&#x04e16;&#x0754c;&#x0536b;&#x0751f;&#x07ec4;&#x07ec7;&#x063a8;&#x08350;&#x07684;&#x07ed3;&#x06838;&#x075c5;&#x09632;&#x063a7;&#x065b9;&#x06cd5;&#x05bf9;&#x04e16;&#x0536b;&#x07ec4;&#x07ec7;&#x0975e;&#x06d32;&#x0533a;&#x057df;&#x000a0;12&#x000a0;&#x056fd;&#x07684;&#x053d1;&#x075c5;&#x07387;&#x05f71;&#x054cd;&#x06700;&#x05927;,&#x08fd9;&#x04e9b;&#x056fd;&#x05bb6;&#x04e0e;&#x04eba;&#x04f53;&#x0514d;&#x075ab;&#x07f3a;&#x09677;&#x075c5;&#x06bd2;&#x000a0;(HIV)&#x000a0;&#x0611f;&#x067d3;&#x06709;&#x05173;&#x07684;&#x080ba;&#x07ed3;&#x06838;&#x075be;&#x075c5;&#x08d1f;&#x062c5;&#x06c89;&#x091cd;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x083b7;&#x05f97;&#x04e86;&#x000a0;2003&#x000a0;&#x05e74;&#x081f3;&#x000a0;2016&#x000a0;&#x05e74;&#x095f4;&#x07684;&#x0827e;&#x06ecb;&#x075c5;&#x0548c;&#x07ed3;&#x06838;&#x075c5;&#x07684;&#x06d41;&#x0884c;&#x075c5;&#x05b66;&#x076d1;&#x06d4b;&#x03001;&#x08c03;&#x067e5;&#x0548c;&#x06cbb;&#x07597;&#x06570;&#x0636e;&#x03002;&#x06211;&#x04eec;&#x091c7;&#x07528;&#x07edf;&#x08ba1;&#x06a21;&#x0578b;&#x06765;&#x068c0;&#x06d4b;&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x0548c;&#x05f02;&#x070df;&#x080bc;&#x09884;&#x09632;&#x06027;&#x07597;&#x06cd5;&#x05728;&#x0964d;&#x04f4e;&#x0827e;&#x06ecb;&#x075c5;&#x06bd2;&#x0611f;&#x067d3;&#x08005;&#x04e2d;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x065b9;&#x09762;&#x07684;&#x07597;&#x06548;&#x03002;&#x06211;&#x04eec;&#x08fd8;&#x07814;&#x07a76;&#x04e86;&#x07ed3;&#x06838;&#x075c5;&#x075c5;&#x04f8b;&#x068c0;&#x06d4b;&#x0548c;&#x06cbb;&#x07597;&#x05728;&#x09884;&#x09632;<italic>&#x07ed3;&#x06838;&#x05206;&#x0679d;&#x06746;&#x083cc;</italic>&#x04f20;&#x064ad;&#x0548c;&#x051cf;&#x05c11;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x065b9;&#x09762;&#x07684;&#x04f5c;&#x07528;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05728;&#x000a0;2003&#x000a0;&#x05e74;&#x081f3;&#x000a0;2016&#x000a0;&#x05e74;&#x095f4;,&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x04e0e;&#x05404;&#x056fd;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x07684;&#x0964d;&#x04f4e;&#x0548c;&#x04e0d;&#x0540c;&#x056fd;&#x05bb6;&#x095f4;&#x04e0b;&#x0964d;&#x07387;&#x07684;&#x05dee;&#x05f02;&#x05747;&#x06709;&#x05173;&#x08054;&#x03002;&#x07531;&#x06b64;&#x063a8;&#x065ad;&#x051fa;&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x0662f;&#x0964d;&#x04f4e;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x07684;&#x0539f;&#x056e0;&#x04e4b;&#x04e00;&#x03002;&#x0636e;&#x04f30;&#x08ba1;,&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x09884;&#x09632;&#x04e86;&#x000a0;188&#x000a0;&#x04e07;(95%&#x000a0;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;,CI:1.65&#x000a0;&#x081f3;&#x000a0;2.11)&#x0827e;&#x06ecb;&#x075c5;&#x06bd2;&#x0643a;&#x05e26;&#x08005;&#x060a3;&#x06709;&#x07ed3;&#x06838;&#x075c5;,&#x06216;&#x000a0;15.7%(95%&#x000a0;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;:13.8&#x000a0;&#x081f3;&#x000a0;17.6)&#x07684;&#x000a0;1196&#x000a0;&#x04e07;&#x04f8b;&#x0827e;&#x06ecb;&#x075c5;&#x06bd2;&#x09633;&#x06027;&#x07ed3;&#x06838;&#x075c5;&#x075c5;&#x04f8b;&#x03002;&#x05f02;&#x070df;&#x080bc;&#x09884;&#x09632;&#x06027;&#x07597;&#x06cd5;&#x07684;&#x04eba;&#x053e3;&#x08986;&#x076d6;&#x07387;&#x08fc7;&#x04f4e;(&#x05408;&#x0683c;&#x08005;&#x05e73;&#x05747;&#x053ea;&#x06709;&#x000a0;1.0%)&#x0ff0c;&#x065e0;&#x06cd5;&#x05bf9;&#x0964d;&#x04f4e;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x04ea7;&#x0751f;&#x08f83;&#x05927;&#x05f71;&#x054cd;,&#x07ed3;&#x06838;&#x075c5;&#x068c0;&#x06d4b;&#x0548c;&#x06cbb;&#x07597;&#x07684;&#x06539;&#x05584;&#x04e0e;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x07684;&#x0964d;&#x04f4e;&#x05448;&#x05f31;&#x076f8;&#x05173;&#x06027;&#x06216;&#x065e0;&#x0663e;&#x08457;&#x076f8;&#x05173;&#x06027;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x04e0e;&#x08fd9;&#x000a0;12&#x000a0;&#x04e2a;&#x056fd;&#x05bb6;&#x07ed3;&#x06838;&#x075c5;&#x053d1;&#x075c5;&#x07387;&#x07684;&#x0964d;&#x04f4e;&#x06709;&#x05173;&#x03002;&#x056e0;&#x06b64;&#x0ff0c;&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x07597;&#x06cd5;&#x000a0;(ART)&#x000a0;&#x04ecd;&#x05e94;&#x0662f;&#x07ed3;&#x06838;&#x075c5;-&#x0827e;&#x06ecb;&#x075c5;&#x06bd2;&#x05408;&#x05e76;&#x0611f;&#x067d3;&#x09ad8;&#x053d1;&#x075c5;&#x07387;&#x05730;&#x0533a;&#x07684;&#x07ed3;&#x06838;&#x075c5;&#x09632;&#x063a7;&#x091cd;&#x070b9;&#x0ff0c;&#x05728;&#x06cbb;&#x07597;&#x07ed3;&#x06838;&#x075c5;&#x065b9;&#x09762;&#x04ecd;&#x09700;&#x0518d;&#x063a5;&#x0518d;&#x05389;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x00418;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00412;&#x00441;&#x00435;&#x0043c;&#x00438;&#x00440;&#x0043d;&#x0043e;&#x00439; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x00431;&#x0043e;&#x00440;&#x0044c;&#x00431;&#x0044b; &#x00441; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;, &#x0043d;&#x00430;&#x00438;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0044e;&#x00449;&#x00438;&#x00445; &#x0043d;&#x00430; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00432; 12&#x000a0;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x00410;&#x00444;&#x00440;&#x00438;&#x0043a;&#x00430;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430; &#x00412;&#x0041e;&#x00417; &#x00441; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x00438;&#x0043c; &#x00431;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043c; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430;, &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441; &#x00438;&#x0043d;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043e;&#x0043c; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043e;&#x00434;&#x00435;&#x00444;&#x00438;&#x00446;&#x00438;&#x00442;&#x00430; &#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430;&#x000a0;(&#x00412;&#x00418;&#x00427;).</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x0043b;&#x00438; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c; &#x0044d;&#x0043f;&#x00438;&#x00434;&#x00435;&#x0043c;&#x00438;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00434;&#x00437;&#x0043e;&#x00440;&#x00430;, &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00412;&#x00418;&#x00427; &#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00437;&#x00430; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 2003 &#x0043f;&#x0043e; 2016&#x000a0;&#x00433;&#x0043e;&#x00434;. &#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x00441;&#x00442;&#x00430;&#x00442;&#x00438;&#x00441;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438; &#x00434;&#x0043b;&#x0044f; &#x00438;&#x00437;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x0043e;&#x00439; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438; &#x00438; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438;&#x00437;&#x0043e;&#x0043d;&#x00438;&#x00430;&#x00437;&#x00438;&#x00434;&#x0043e;&#x0043c; &#x00434;&#x0043b;&#x0044f; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x00441;&#x00442;&#x00440;&#x00430;&#x00434;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00412;&#x00418;&#x00427;. &#x00422;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00430; &#x00440;&#x0043e;&#x0043b;&#x0044c; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00435;&#x00440;&#x00435;&#x00434;&#x00430;&#x00447;&#x00438; <italic>Mycobacterium tuberculosis</italic> &#x00438;, &#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;, &#x00434;&#x0043b;&#x0044f; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00412; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 2003 &#x0043f;&#x0043e; 2016&#x000a0;&#x00433;&#x0043e;&#x00434; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x0043e;&#x00439; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043e; &#x00441;&#x0043e; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00432; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00439; &#x00438;&#x00437; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00441; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x00432; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x0043c;&#x00438;. &#x00415;&#x00441;&#x0043b;&#x00438; &#x00438;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00438;&#x00442;&#x0044c; &#x00438;&#x00437; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x00447;&#x00442;&#x0043e; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x00430;&#x0044f; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x0044f; &#x00441;&#x0043b;&#x00443;&#x00436;&#x00438;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x00438;&#x00447;&#x00438;&#x0043d;&#x0043e;&#x00439; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;, &#x0043e;&#x0043d;&#x00430; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00433;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00442;&#x00438;&#x00442;&#x0044c; 1,88&#x000a0;&#x0043c;&#x0043b;&#x0043d; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430;&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: &#x0043e;&#x00442; 1,65 &#x00434;&#x0043e; 2,11) &#x00443; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x00441;&#x00442;&#x00440;&#x00430;&#x00434;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00412;&#x00418;&#x00427;, &#x00438;&#x0043b;&#x00438; 15,7%&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: &#x0043e;&#x00442; 13,8 &#x00434;&#x0043e; 17,6) &#x00438;&#x00437; 11,96&#x000a0;&#x0043c;&#x0043b;&#x0043d; &#x0043e;&#x00436;&#x00438;&#x00434;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x00445; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00441; &#x00441;&#x0043e;&#x0043f;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00435;&#x00439; &#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00435;&#x00439; &#x00412;&#x00418;&#x00427;. &#x0041e;&#x00445;&#x00432;&#x00430;&#x00442; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x0043c; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00438;&#x00437;&#x0043e;&#x0043d;&#x00438;&#x00430;&#x00437;&#x00438;&#x00434;&#x0043e;&#x0043c; &#x00431;&#x0044b;&#x0043b; &#x00441;&#x0043b;&#x00438;&#x00448;&#x0043a;&#x0043e;&#x0043c; &#x0043d;&#x00438;&#x00437;&#x0043a;&#x00438;&#x0043c;&#x000a0;(&#x00432; &#x00441;&#x00440;&#x00435;&#x00434;&#x0043d;&#x00435;&#x0043c; 1,0% &#x0043b;&#x00438;&#x00446;, &#x0043e;&#x00442;&#x00432;&#x00435;&#x00447;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x0043a;&#x00440;&#x00438;&#x00442;&#x00435;&#x00440;&#x00438;&#x0044f;&#x0043c;), &#x00447;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x0044c; &#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;, &#x00430; &#x00443;&#x0043b;&#x00443;&#x00447;&#x00448;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00441;&#x0043b;&#x00430;&#x00431;&#x0043e; &#x00438;&#x0043b;&#x00438; &#x0043d;&#x00435;&#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0044b; &#x00441;&#x0043e; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00410;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x00430;&#x0044f; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x0044f; &#x00430;&#x00441;&#x00441;&#x0043e;&#x00446;&#x00438;&#x00438;&#x00440;&#x00443;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00441;&#x0043e; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; 12&#x000a0;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;. &#x00410;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x00430;&#x0044f; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x0044f; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x00430; &#x00438; &#x00432;&#x0043f;&#x00440;&#x00435;&#x00434;&#x0044c; &#x00437;&#x00430;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x00442;&#x0044c; &#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x0043c;&#x00435;&#x00441;&#x00442;&#x0043e; &#x00432; &#x00431;&#x0043e;&#x00440;&#x0044c;&#x00431;&#x00435; &#x00441; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x0043e;&#x0043c; &#x00432; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;, &#x00433;&#x00434;&#x00435; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00438; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430; &#x00441; &#x00441;&#x0043e;&#x0043f;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00435;&#x00439; &#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00435;&#x00439; &#x00412;&#x00418;&#x00427; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x00438;, &#x0043d;&#x0043e; &#x0043d;&#x00435;&#x0043e;&#x00431;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0043e; &#x00432;&#x0043e;&#x00437;&#x0043e;&#x00431;&#x0043d;&#x0043e;&#x00432;&#x00438;&#x00442;&#x0044c; &#x00443;&#x00441;&#x00438;&#x0043b;&#x00438;&#x0044f; &#x00432; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00448;&#x00435;&#x0043d;&#x00438;&#x00438; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00442;&#x00443;&#x00431;&#x00435;&#x00440;&#x0043a;&#x00443;&#x0043b;&#x00435;&#x00437;&#x00430;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Among people with latent <italic>Mycobacterium tuberculosis </italic>infection, coinfection with the human immunodeficiency virus (HIV) carries a 10- to 15-fold risk of developing active tuberculosis.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>&#x02013;</sup><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> From 2003 to 2016, the countries worst-affected by the HIV epidemic, including Botswana, Eswatini and Lesotho reported national adult (15&#x02013;49&#x000a0;years) HIV prevalence of over 20% and exceptionally high national tuberculosis incidence rates above 500 per 100&#x02009;000 population per year (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>).<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Across the WHO African Region in 2016, there were an estimated 764&#x02009;000 new cases of tuberculosis among people living with HIV, leading to 320&#x02009;000 deaths.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref></p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Tuberculosis and HIV epidemics in 12 countries in the WHO African Region, 2003&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="58" span="1"/><col width="62" span="1"/><col width="77" span="1"/><col width="70" span="1"/><col width="63" span="1"/><col width="70" span="1"/><col width="63" span="1"/><col width="63" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Country</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">HIV prevalence, %<hr/></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Tuberculosis incidence per 100&#x02009;000 people per year<sup>c</sup><hr/></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Change in tuberculosis incidence, % per year<sup>d</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Total population<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Tuberculosis patients<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total tuberculosis patients</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">HIV-positive tuberculosis patients</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total tuberculosis patients</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">HIV-positive tuberculosis patients</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">HIV-negative tuberculosis patients</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Botswana</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">816</td><td valign="top" align="center" rowspan="1" colspan="1">571</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;6.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Eswatini</td><td valign="top" align="center" rowspan="1" colspan="1">27</td><td valign="top" align="center" rowspan="1" colspan="1">84</td><td valign="top" align="center" rowspan="1" colspan="1">1280</td><td valign="top" align="center" rowspan="1" colspan="1">973</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;6.8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kenya</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">397</td><td valign="top" align="center" rowspan="1" colspan="1">331</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.6</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lesotho</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">1280</td><td valign="top" align="center" rowspan="1" colspan="1">979</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malawi</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="center" rowspan="1" colspan="1">397</td><td valign="top" align="center" rowspan="1" colspan="1">283</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Namibia</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">59</td><td valign="top" align="center" rowspan="1" colspan="1">935</td><td valign="top" align="center" rowspan="1" colspan="1">552</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;9.0</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rwanda</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">45</td><td valign="top" align="center" rowspan="1" colspan="1">102</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">South Africa</td><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">65</td><td valign="top" align="center" rowspan="1" colspan="1">977</td><td valign="top" align="center" rowspan="1" colspan="1">607</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Uganda</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">59</td><td valign="top" align="center" rowspan="1" colspan="1">248</td><td valign="top" align="center" rowspan="1" colspan="1">146</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.3</td><td valign="top" align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">United Republic of Tanzania</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">510</td><td valign="top" align="center" rowspan="1" colspan="1">243</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zambia</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">662</td><td valign="top" align="center" rowspan="1" colspan="1">445</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zimbabwe</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">78</td><td valign="top" align="center" rowspan="1" colspan="1">617</td><td valign="top" align="center" rowspan="1" colspan="1">471</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;8.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;6.0</td></tr></tbody></table><table-wrap-foot><p>HIV: human immunodeficiency virus.</p><p><sup>a</sup> Prevalence of HIV infection in people aged 15&#x02013;49 years.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref></p><p><sup>b</sup> Values are maximum percentages of HIV infection in new tuberculosis patients.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p><sup>c</sup> Values are maximum estimates of tuberculosis incidence and HIV-positive tuberculosis incidence.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p><sup>d</sup> Average annual rate of change in HIV-positive, HIV-negative, and all tuberculosis incidence rate per 100&#x02009;000 population. Negative values represent declining incidence.</p></table-wrap-foot></table-wrap><p>To reduce the incidence of tuberculosis in populations with a high proportion of <italic>M.&#x000a0;tuberculosis</italic> and HIV coinfection, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) primarily recommend drug treatments such as isoniazid preventive therapy and antiretroviral therapy (ART) to prevent progression from latent to active tuberculosis. ART protects against tuberculosis by facilitating the restoration of immune function in people living with HIV, thus impeding progression of latent <italic>M.&#x000a0;tuberculosis</italic> infection to active tuberculosis. Isoniazid preventive therapy, when used continuously with ART, generally gives coinfected adults additional protection from tuberculosis.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>&#x02013;</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref> WHO and UNAIDS also recommend combinations of drugs to prevent onward transmission of infection from patients with active tuberculosis.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Combination chemotherapy and ART are the two principal interventions used to reduce tuberculosis incidence and have the greatest population coverage and longest history of use. The efficacy of all these treatments has been demonstrated in experimental and observational studies<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>&#x02013;</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref><sup>&#x02013;</sup><xref rid="R14" ref-type="bibr"><sup>14</sup></xref> and drug treatments have the potential markedly to reduce incidence if high rates of treatment coverage can be achieved in target populations.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R15" ref-type="bibr"><sup>15</sup></xref><sup>&#x02013;</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><p>The purpose of this study was to investigate which of these recommended drug treatment methods have had the greatest impact on tuberculosis incidence in 12 countries in the WHO African Region with high burdens of tuberculosis linked to HIV infection (further information available from our data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p><p>We used biologically-informed statistical models, together with data routinely collected annually since 1990, to examine the effects of ART and isoniazid preventive therapy in preventing tuberculosis disease in people living with HIV, and to investigate tuberculosis case detection and combination chemotherapy treatment as a means of interrupting <italic>M.&#x000a0;tuberculosis</italic> transmission to reduce tuberculosis incidence. We used a retrospective longitudinal design to investigate each country and cross-sectional analysis to compare the countries.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data sources</title><p>We obtained publicly available epidemiological surveillance, survey and treatment data on tuberculosis and HIV from WHO<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> and UNAIDS.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Population data are from the 2017 Revision of World Population Prospects.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></p></sec><sec><title>Study setting</title><p>We chose 12 countries in the WHO African Region that had high tuberculosis&#x02013;HIV coinfection rates and sufficient data to do this investigation: Botswana, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, South Africa, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. We excluded Mozambique because the trend in tuberculosis incidence was unclear from the series of annual case notifications: the number of cases reported increased continuously between 2002 and 2016, probably because the proportion of incident cases detected was increasing over that period and not because of a true rise in incidence (available from the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p></sec><sec><title>Intervention models</title><p>Since interventions to stop tuberculosis progression and transmission have different modes of action, we investigated the interventions, using two separate univariate models, rather than combining the interventions in one multivariate model.</p><p>We modelled the effect of ART on tuberculosis incidence by using the equation<disp-formula id="E1"><graphic xlink:href="BLT.18.228577-M1.jpg" position="anchor" orientation="portrait"/><label>(1)</label></disp-formula>where <italic>T</italic> is the annual incidence rate of tuberculosis among people living with HIV in year <italic>t</italic>. In this model <italic>&#x003b1;</italic> is the per capita incidence rate of tuberculosis in the untreated population of people living with HIV (<italic>H</italic>) after a delay of <italic>&#x003c4;</italic>&#x000a0;years, which depends on the prevalence and incubation period of <italic>M.&#x000a0;tuberculosis</italic> in HIV-positive individuals and on the average age of HIV infection in the population (further details in the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> In the absence of drug treatment for either <italic>M.&#x000a0;tuberculosis</italic> or HIV infection, <italic>&#x003b1;</italic> would change little over the period 2003&#x02013;2016, so we took <italic>&#x003b1;</italic> to be constant over the time span of this study. <italic>A</italic> is the fraction of people living with HIV receiving ART, which takes effect after <italic>&#x003c4;</italic>&#x000a0;years, and coefficient <italic>&#x003b2;</italic>&#x000a0;scales the effect of ART under the hypothesis that ART prevents tuberculosis. Neither this model, nor this analysis, accounts for the separate effects of ART on HIV, which are to interrupt viral transmission and increase population prevalence by improving survival and life expectancy.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>&#x02013;</sup><xref rid="R22" ref-type="bibr"><sup>22</sup></xref></p><p>For each of the 12 countries, <italic>T</italic> is obtained from routine surveillance data (annual tuberculosis case notifications) and the estimated proportion of tuberculosis cases infected with HIV.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Variables <italic>H</italic> and <italic>A</italic> are national estimates derived from national and subnational survey data.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Rewriting the model as<disp-formula id="E2"><graphic xlink:href="BLT.18.228577-M2.jpg" position="anchor" orientation="portrait"/><label>(2)</label></disp-formula>parameters <italic>&#x003b1;</italic> and <italic>&#x003b2;</italic> are estimated from a linear regression of<inline-formula><inline-graphic xlink:href="BLT.18.228577-M3.jpg"/></inline-formula> on <italic>A<sub>t-&#x003c4;</sub></italic>, with intercept <italic>&#x003b1;</italic> and gradient - <italic>&#x003b1;&#x003b2;</italic>. The time delay, <italic>&#x003c4;</italic>, was set at 2&#x000a0;years, based on the fit of the regression model to data, and on the recovery rate of CD4+ T-lymphocyte count after patients are started on ART (further details in the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref> The number of people living with HIV that are prevented from developing tuberculosis is obtained from the fit of the model to data comparing the number of tuberculosis cases expected under the hypothesis that ART prevents (<italic>&#x003b2;</italic>&#x02009; &#x0003e;&#x02009;0, estimated) or does not prevent (<italic>&#x003b2;</italic>&#x02009;&#x02009;=&#x02009;0, counterfactual) tuberculosis.</p><p>We modelled the effect of tuberculosis case detection and combination chemotherapy treatment on tuberculosis incidence, via reduced transmission, using the model<disp-formula id="E3"><graphic xlink:href="BLT.18.228577-M4.jpg" position="anchor" orientation="portrait"/><label>(3)</label></disp-formula>where <italic>T<sub>t</sub></italic>and <italic>T<sub>t-&#x003c4;</sub></italic> represent the incidence of all tuberculosis cases (regardless of HIV status) in the population. Coefficient <italic>r</italic> is the tuberculosis case reproduction number over the period <italic>&#x003c4;</italic> in the absence of drug treatment. <italic>D<sub>t-&#x003c4;</sub></italic>is the proportion of all tuberculosis cases detected and successfully treated (that is, cases that converted from bacteriologically positive to negative, or completed treatment) and <italic>&#x003b4;</italic> scales the effect of <italic>D<sub>t-&#x003c4;</sub></italic> in reducing <italic>M.&#x000a0;tuberculosis</italic> transmission. Rewriting the model as<disp-formula id="E4"><graphic xlink:href="BLT.18.228577-M5.jpg" position="anchor" orientation="portrait"/><label>(4)</label></disp-formula>parameters <italic>r</italic> and <italic>&#x003b4;</italic> are estimated from a linear regression of<inline-formula><inline-graphic xlink:href="BLT.18.228577-M6.jpg"/></inline-formula> on <italic>D<sub>t-&#x003c4;</sub></italic>, with intercept <italic>r</italic> and gradient -<italic>r&#x003b4;</italic>. The regression analysis is a test of whether an increase in case detection and treatment success accelerates the decline in tuberculosis incidence by reducing transmission. <italic>D</italic> is calculated from estimates of the proportion of all tuberculosis cases detected in any given year multiplied by the proportion successfully treated, which is reported by WHO in the following year (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> The time delay, <italic>&#x003c4;</italic>, was set at 2&#x000a0;years, but the conclusions of the analysis were not sensitive to the length of the delay (available from the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Trends in detection and treatment success of people with tuberculosis, 12 countries in the WHO African Region, 2000&#x02013;2016</p></caption><p>HIV: human immunodeficiency virus.</p><p>Notes: Data are the estimated percentage of tuberculosis cases detected (constant through time in some countries), the measured proportion of tuberculosis cases successfully treated by combination chemotherapy, and the proportion of HIV-positive (HIV+) tuberculosis cases successfully treated where data are available. </p><graphic xlink:href="BLT.18.228577-F1"/></fig><p>We performed all analysis in Excel (Microsoft, Redmond, United States of America).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Between 1990 and 2016, all 12 countries showed similar trends for tuberculosis and HIV epidemics and their control measures (available from the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref>
<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> shows Botswana and South Africa as examples. The numbers of tuberculosis cases reported each year increased following the rise of HIV incidence and prevalence. The subsequent downturn in tuberculosis incidence in both countries appeared to be associated with improvements in the proportion of tuberculosis cases successfully treated (that is, the proportion of cases detected&#x02009;&#x000d7;&#x02009;proportion successfully treated), but more obviously corresponded with the expanded coverage of ART. The scale-up of ART coverage from 2003 onwards was more rapid in Botswana than in South Africa, and the decline in tuberculosis incidence occurred earlier and more quickly. In the countries investigated here, the proportional decline and the absolute magnitude of the decline were greater for HIV-positive than for HIV-negative patients with tuberculosis (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>). The provision of isoniazid preventive therapy was low in both Botswana and South Africa, compared to the coverage of ART and to the proportion of tuberculosis patients treated with combination chemotherapy.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Trends in tuberculosis and HIV epidemics and treatments in Botswana and South Africa, 1990&#x02013;2016</p></caption><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus.</p><p>Notes: Estimated HIV incidence and prevalence show data for adults (15&#x02013;49&#x000a0;years). Coverages for ART and isoniazid preventive therapy are in the adult population.</p><p>Data source: World Health Organization and the Joint United Nations Programme on HIV/AIDS.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><graphic xlink:href="BLT.18.228577-F2"/></fig><p>ART coverage increased in all 12 countries between 2003 and 2016 (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>) as tuberculosis incidence declined among people living with HIV (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>; data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> While the changes in ART coverage and tuberculosis incidence are inversely correlated (available from the data repository),<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> these correlations do not prove that ART was the cause of tuberculosis decline in these countries. Other unmeasured factors, including other interventions, could confound the correlations. However, the evidence for a causal role of ART is strengthened by comparing the results of regression analysis across all 12 countries: we found that the estimated fraction of HIV-positive tuberculosis cases prevented by ART was associated with the provision of ART across all countries (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>; <italic>r</italic><sup>2</sup>&#x02009;=&#x02009;0.68; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Trends in HIV incidence, HIV prevalence and ART coverage, 12 countries in the WHO African Region, 2003&#x02013;2016</p></caption><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus.</p><p>Notes: The ratio of ART coverage to HIV prevalence is the coverage of ART in people living with HIV. </p><graphic xlink:href="BLT.18.228577-F3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Trends in tuberculosis incidence in people living with HIV, 12 countries in the WHO African Region, 2003&#x02013;2016</p></caption><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus.</p><p>Notes: Data are the estimated incidence of HIV-positive tuberculosis cases per 100&#x02009;000 population per year. Solid lines represent the fit of the model under the hypothesis that ART prevents (for regression coefficients <italic>&#x003b2;</italic> &#x0003e;&#x02009;1, lower lines) or does not prevent tuberculosis (counterfactual <italic>&#x003b2;</italic>&#x02009;=&#x02009;0, upper lines). The number of cases prevented in each country is calculated from the area between upper and lower lines.</p><graphic xlink:href="BLT.18.228577-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Association between antiretroviral coverage and tuberculosis incidence in people living with HIV, 12 countries in the WHO African Region, 2003&#x02013;2016</p></caption><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus.</p><p>Notes: In our model, ART coverage explains 68% of the variation in the estimated percentage of HIV-positive tuberculosis cases prevented (<italic>P</italic>&#x02009;=&#x02009;0.0009). </p><graphic xlink:href="BLT.18.228577-F5"/></fig><p>The average ART coverage was highest and contributed to the greatest proportions of HIV-positive tuberculosis cases prevented in Botswana, Namibia and Rwanda (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). South Africa, the country with the largest number of people living with HIV (7.1 million in 2016),<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> prevented the greatest number of HIV-positive tuberculosis cases (543&#x02009;000) between 2003 and 2016, but the smallest fraction of such cases (11.2%; 542911/4846209) because ART coverage was low, on average 21.8%.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Interventions to reduce tuberculosis incidence in 12 countries in the WHO African Region, 2003&#x02013;2016</title></caption><table frame="hsides" rules="groups"><col width="52" span="1"/><col width="52" span="1"/><col width="66" span="1"/><col width="86" span="1"/><col width="105" span="1"/><col width="66" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Country</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Average ART coverage</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Detection and treatment success of people with tuberculosis<sup>a</sup><hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Average % of HIV-positive people on isoniazid preventive therapy<sup>b</sup></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">No. of coinfected tuberculosis cases prevented (%)<sup>c</sup></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Average(%)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Change(%/year)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Botswana</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">12.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.51</td><td valign="top" align="center" rowspan="1" colspan="1">48&#x02009;000 (30)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Eswatini</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">91.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.17</td><td valign="top" align="center" rowspan="1" colspan="1">54&#x02009;000 (27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kenya</td><td valign="top" align="center" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">6.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.56</td><td valign="top" align="center" rowspan="1" colspan="1">392&#x02009;000 (21)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lesotho</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">10.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.11</td><td valign="top" align="center" rowspan="1" colspan="1">75&#x02009;000 (23)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Malawi</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;9.0</td><td valign="top" align="center" rowspan="1" colspan="1">3.09</td><td valign="top" align="center" rowspan="1" colspan="1">111&#x02009;000 (19)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Namibia</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">61</td><td valign="top" align="center" rowspan="1" colspan="1">30.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.44</td><td valign="top" align="center" rowspan="1" colspan="1">55&#x02009;000 (31)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rwanda</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">62</td><td valign="top" align="center" rowspan="1" colspan="1">14.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td><td valign="top" align="center" rowspan="1" colspan="1">19&#x02009;000 (30)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">South Africa</td><td valign="top" align="center" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">28.2</td><td valign="top" align="center" rowspan="1" colspan="1">4.21</td><td valign="top" align="center" rowspan="1" colspan="1">543&#x02009;000 (11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Uganda</td><td valign="top" align="center" rowspan="1" colspan="1">27</td><td valign="top" align="center" rowspan="1" colspan="1">44</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td><td valign="top" align="center" rowspan="1" colspan="1">72&#x02009;000 (11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">United Republic of Tanzania</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">16.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.18</td><td valign="top" align="center" rowspan="1" colspan="1">195&#x02009;000 (13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zambia</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">56</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.02</td><td valign="top" align="center" rowspan="1" colspan="1">165&#x02009;000 (20)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zimbabwe</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="center" rowspan="1" colspan="1">21.1</td><td valign="top" align="center" rowspan="1" colspan="1">2.93</td><td valign="top" align="center" rowspan="1" colspan="1">149&#x02009;000 (18)</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral therapy; HIV: human immunodeficiency virus.</p><p><sup>a</sup> Average and change in the number of tuberculosis cases detected and successfully treated for the years 2003 to 2016.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p><sup>b</sup> Coverage (%) calculated as: total number of people living with HIV who start treatment/total number of people living with HIV, aged 15&#x02013;49 years.</p><p><sup>c</sup> Estimated number and percentage of HIV-positive tuberculosis cases prevented by ART, 2003&#x02013;2016.</p></table-wrap-foot></table-wrap><p>Based on the fit of the model to data for each of the countries between 2003 and 2016 (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>; data repository),<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> ART prevented 1.88&#x000a0;million (95% confidence interval, CI: 1.65 to 2.11) people living with HIV from developing active tuberculosis, or 15.7% (95% CI: 13.8 to 17.6) of the 11.96 million HIV-positive tuberculosis cases expected. An alternative way of calculating the number of cases prevented is to use the association between cases prevented and ART coverage across the 12 countries (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>): summing the predictions for each country gives a similar total of 2.06 million people living with HIV prevented from developing active tuberculosis over the same period, or 17.3% of the number of HIV-positive cases expected.</p><p>Although the primary effect of ART is to stop progression from <italic>M.&#x000a0;tuberculosis</italic> infection to tuberculosis disease in people living with HIV, the consequent reduction in tuberculosis incidence might also reduce onward transmission. The incidence of tuberculosis in HIV-negative people declined in all countries alongside tuberculosis in HIV-positive people, albeit more slowly (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>) and, comparing countries, the rates of decline in HIV-positive and HIV-negative tuberculosis were correlated (<italic>r</italic><sup>2</sup>&#x02009;=&#x02009;0.48; <italic>P</italic>&#x02009;=&#x02009;0.02).</p><p>Considering the treatment of tuberculosis infection or disease (rather than of HIV infection), neither combination chemotherapy for tuberculosis, nor the prophylactic treatment of <italic>M. tuberculosis</italic> infection with isoniazid, markedly accelerated the decline in tuberculosis incidence between 2003 and 2016. The evidence is as follows: First, the detection of infectious pulmonary tuberculosis cases at an early stage of illness followed by successful drug treatment should interrupt the transmission of <italic>M.&#x000a0;tuberculosis</italic> from all patients regardless of HIV status, thereby reducing tuberculosis incidence in the rest of the population.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="R15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Comparing countries, the rate of decline in tuberculosis incidence is expected to be faster where case detection and treatment success are higher on average. The national proportions of all tuberculosis cases detected and successfully treated varied between 27.5% and 62.2% (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). There was no discernible association between tuberculosis case detection or treatment and tuberculosis incidence across the countries (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>; <italic>r</italic><sup>2</sup>&#x02009;=&#x02009;0.06, P = 0.65).</p><p>If case detection and treatment success improve with time in any individual country, we expect to see an accelerated decline in tuberculosis incidence as the interruption of transmission lowers the tuberculosis case reproduction number. Tuberculosis case detection and treatment did improve somewhat in most countries between 2003 and 2016 as tuberculosis incidence declined, though not in Malawi, Uganda and Zambia (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>; <xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). Within each country, there were either weak associations (Eswatini, South Africa, Zimbabwe) or no significant associations (the other nine countries) between tuberculosis case detection and treatment success, and the rate of decline in tuberculosis incidence (available from the data repository).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> In summary, neither the levels nor the change in tuberculosis case detection and treatment success can explain the reduction in tuberculosis incidence observed in all 12 countries from around 2003 onwards (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>).</p><p>Second, we examined isoniazid preventive therapy in the 12 countries and found that the coverage of such therapy among people living with HIV was generally low between the years 2003 and 2016 (average 1.0% of persons eligible across countries; <xref rid="T2" ref-type="table">Table&#x000a0;2</xref>). In 2016, South Africa started the largest number of people on isoniazid preventive therapy, 385&#x02009;932 people, or 51.3% of those 751620 people newly enrolled in care for HIV/acquired immunodeficiency syndrome (AIDS) that year. However, only 4.2% of people living with HIV, on average, received isoniazid preventive therapy between 2003 and 2016, contrasted with an average of 21.8% who started ART during the same period. In comparison, an average 3.1% of people living with HIV in Malawi and 2.9% of people living with HIV in Zimbabwe received isoniazid preventive therapy. These three countries together reported 91.0% (3.28 million/3.61 million) of all people living with HIV who had started isoniazid preventive therapy in the 12 countries by 2016. Thus, isoniazid preventive therapy may have protected thousands of coinfected people from developing tuberculosis in Malawi, South Africa and Zimbabwe, but the effect on tuberculosis incidence at a population level would have been small in these three countries, and negligible in the other nine countries.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Our analysis suggests that the roll-out of ART, supported by the services needed to provide treatment, such as HIV testing, drug procurement, treatment supervision, outcome monitoring and nutritional supplements, has played a major part in the tuberculosis decline in southern and eastern Africa since 2003. Our results are broadly in line with a previous study<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> that also found an association between ART coverage and the reduction in tuberculosis incidence among people living with HIV.</p><p>By stopping the progression from <italic>M. tuberculosis</italic> infection to tuberculosis disease, we estimated that ART prevented 1.88 million HIV-positive tuberculosis cases between 2003 and 2016. If ART also reduced the transmission of <italic>M. tuberculosis</italic> infections, as suggested by this analysis, then our estimate of prevented tuberculosis cases would be conservative. In contrast, we did not identify any evidence that drug treatment of tuberculosis infection or disease played more than a minor role in accelerating the rate of tuberculosis decline.</p><p>This study has limitations. Given the well-known uncertainties in measuring the coverage of tuberculosis control programmes, we cannot be sure that improvements in case detection and treatment success did not accelerate the decline in tuberculosis incidence. Moreover, our study was an analysis of change; we did not investigate, and therefore cannot quantify, the effect of a constant rate of case detection and treatment in reducing transmission and tuberculosis incidence.</p><p>We found large variations among countries in the estimated fraction of tuberculosis cases prevented by ART. These variations were linked to differences in ART coverage. Future research should investigate both the immediate and deeper reasons for differences in coverage, because these reasons are likely to influence the future success of HIV and tuberculosis control programmes. Between 2003 and 2016, Botswana prevented the largest fraction of tuberculosis cases and achieved the highest coverage of ART. Since independence in 1966, Botswana has invested in public services to tackle ill health and poverty<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and was the first African country to provide universal, free-of-charge ART.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> South Africa prevented the smallest fraction of tuberculosis cases among the countries investigated. Following controversy over the link between HIV and AIDS,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> South Africa was slower to expand treatment for people living with HIV, but now has the largest number of people on ART and isoniazid preventive therapy worldwide.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R11" ref-type="bibr"><sup>11</sup></xref> In 2015, South Africa became the first country in sub-Saharan Africa to issue full regulatory approval for pre-exposure prophylaxis, using ART to protect HIV-negative people from acquiring HIV infection.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> Consistent with these recent developments in South Africa, the rate of tuberculosis decline among people living with HIV increased to 4.6% per year between 2010 and 2016 (compared with the average decline of 0.5% per year over the period 2003&#x02013;2016; <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>).</p><p>The number of patients with tuberculosis tested for HIV infection across Africa has greatly increased. In 2016, 82% of reported tuberculosis patients had a documented HIV test result, up from 2% in 2004.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Once tested positive for HIV, tuberculosis patients become eligible for ART, increasing the chance of successful tuberculosis treatment and reducing the risk of death. However, far less progress has been made in finding and treating tuberculosis among people living with HIV and among HIV-negative people living in settings with high prevalence of coinfection, both forms of progress are imperative for control, and ultimately, for the elimination of tuberculosis.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> To find individuals with infectious tuberculosis earlier requires a greater awareness of the risk of tuberculosis among people living with HIV and a more active approach to tuberculosis diagnosis at home, in the community and in health facilities.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>&#x02013;</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></p><p>While millions of people living with HIV now receive ART continuously in southern and eastern Africa, a small number also receive isoniazid preventive therapy.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref> In this context, the success of Malawi, South Africa and Zimbabwe in starting patients on isoniazid preventive therapy will improve knowledge on how to identify candidates for isoniazid preventive therapy (recognizing that efficacy is greater for those who are tuberculin skin test positive and that patients with tuberculosis disease must be excluded), maintain adherence to prolonged prophylaxis (daily treatment for at least 6&#x000a0;months), and manage the adverse reactions that affect a small fraction of patients on isoniazid.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></p><p>Tuberculosis accounted for 1.7 million deaths in 2016, including those among HIV-positive cases<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> and tuberculosis incidence is declining too slowly to reach international targets. For example, the WHO End TB Strategy aims to cut the tuberculosis incidence worldwide by 80% between 2015 and 2030, which requires a fivefold increase in the rate of decline, from 2% per year at present to at least 10% per year.</p><p>The slow pace of technological development in tuberculosis control, including diagnostics, drugs and vaccines<xref rid="R6" ref-type="bibr"><sup>6</sup></xref>, provides a strong argument for making the best use of the tools that are currently available. The best strategies may vary from one setting to another, but for populations having a high or increasing prevalence of tuberculosis&#x02013;HIV coinfection, ART is an effective intervention. However, the scale-up of ART alone will not be enough to reach international targets. Besides the search for new interventions and technologies, additional efforts are needed to maximize the benefits of directly treating tuberculosis infection and disease.</p></sec></body><back><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Williams</surname>
<given-names>BG</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>. <article-title>Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.</article-title>
<source>Science</source>. <year>2003</year>
<month>9</month>
<day>12</day>;<volume>301</volume>(<issue>5639</issue>):<fpage>1535</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.1086845</pub-id><pub-id pub-id-type="pmid">12920302</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Williams</surname>
<given-names>BG</given-names></string-name>, <string-name><surname>Granich</surname>
<given-names>R</given-names></string-name>, <string-name><surname>De Cock</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Glaziou</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sharma</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>. <article-title>Antiretroviral therapy for tuberculosis control in nine African countries.</article-title>
<source>Proc Natl Acad Sci USA</source>. <year>2010</year>
<month>11</month>
<day>9</day>;<volume>107</volume>(<issue>45</issue>):<fpage>19485</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1005660107</pub-id><pub-id pub-id-type="pmid">20974976</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="book"><string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>. <source>The population biology of tuberculosis.</source>
<publisher-loc>Princeton</publisher-loc>: <publisher-name>Princeton University Press</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">UNAIDS DATA. 2017. Geneva: Joint United Nations Programme on HIV/AIDS; 2019. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/resources/documents/2017/2017_data_book">http://www.unaids.org/en/resources/documents/2017/2017_data_book</ext-link> [cited 2019 Apr 15].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Tuberculosis data. Geneva: World Health Organization; 2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/tb/data/en/">https://www.who.int/tb/data/en/</ext-link> [cited 2019 Apr 15].</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="book"><source>Global tuberculosis report 2017.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2017</year>.</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Rangaka</surname>
<given-names>MX</given-names></string-name>, <string-name><surname>Wilkinson</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Boulle</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Glynn</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Fielding</surname>
<given-names>K</given-names></string-name>, <string-name><surname>van Cutsem</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.</article-title>
<source>Lancet</source>. <year>2014</year>
<month>8</month>
<day>23</day>;<volume>384</volume>(<issue>9944</issue>):<fpage>682</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60162-8</pub-id><pub-id pub-id-type="pmid">24835842</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Danel</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Moh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gabillard</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Badje</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Le Carrou</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ouassa</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>; <collab>TEMPRANO ANRS 12136 Study Group</collab>. <article-title>A trial of early antiretrovirals and isoniazid preventive therapy in Africa.</article-title>
<source>N Engl J Med</source>. <year>2015</year>
<month>8</month>
<day>27</day>;<volume>373</volume>(<issue>9</issue>):<fpage>808</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1507198</pub-id><pub-id pub-id-type="pmid">26193126</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Badje</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gabillard</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gu&#x000e9;hi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kabran</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ntakp&#x000e9;</surname>
<given-names>JB</given-names></string-name>, <etal>et al.</etal>; <collab>Temprano ANRS 12136 Study Group</collab>. <article-title>Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.</article-title>
<source>Lancet Glob Health</source>. <year>2017</year>
<season>Nov </season><day>1</day>;<volume>5</volume>(<issue>11</issue>):<fpage>e1080</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(17)30372-8</pub-id><pub-id pub-id-type="pmid">29025631</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="book"><source>Latent tuberculosis infection: updated and consolidated guidelines for programmatic management.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="web">Ending AIDS: progress towards the 90&#x02013;90&#x02013;90 targets. Geneva: Joint United Nations Programme on HIV/AIDS; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017">http://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017</ext-link> [cited 2019 Apr 4]. </mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Akolo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Adetifa</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Shepperd</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Volmink</surname>
<given-names>J</given-names></string-name>. <article-title>Treatment of latent tuberculosis infection in HIV infected persons.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2010</year>
<month>1</month>
<day>20</day>;(<issue>1</issue>):<elocation-id>CD000171</elocation-id>. <pub-id pub-id-type="pmid">20091503</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Samandari</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Agizew</surname>
<given-names>TB</given-names></string-name>, <string-name><surname>Nyirenda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tedla</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Sibanda</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Shang</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.</article-title>
<source>Lancet</source>. <year>2011</year>
<month>5</month>
<day>7</day>;<volume>377</volume>(<issue>9777</issue>):<fpage>1588</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60204-3</pub-id><pub-id pub-id-type="pmid">21492926</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Suthar</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Lawn</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>del Amo </surname><given-names>J</given-names></string-name>, <string-name><surname>Getahun</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sculier</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.</article-title>
<source>PLoS Med</source>. <year>2012 </year><month>7</month>
<day>24</day>;<volume>9</volume><issue>(7)</issue>:<elocation-id>e1001270</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001270</pub-id><pub-id pub-id-type="pmid">22911011</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Currie</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>BG</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>. <article-title>Tuberculosis epidemics driven by HIV: is prevention better than cure?</article-title>
<source>AIDS</source>. <year>2003</year>
<month>11</month>
<day>21</day>;<volume>17</volume>(<issue>17</issue>):<fpage>2501</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/00002030-200311210-00013</pub-id><pub-id pub-id-type="pmid">14600522</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Middelkoop</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bekker</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Myer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Kloos</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Morrow</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2011</year>
<month>3</month>
<day>1</day>;<volume>56</volume>(<issue>3</issue>):<fpage>263</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e31820413b3</pub-id><pub-id pub-id-type="pmid">21317585</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Reid</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Grant</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>White</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vynnycky</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Fielding</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2015</year>
<month>1</month>;<volume>19</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.14.0078</pub-id><pub-id pub-id-type="pmid">25519784</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><string-name><surname>Appendix</surname>
<given-names>DW</given-names></string-name>. <source>Bull WHO.</source>
<publisher-loc>London</publisher-loc>: <publisher-name>Figshare</publisher-name>; <year>2019</year>, .<pub-id pub-id-type="doi">10.6084/m9.figshare.7993502.v1</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="web">Population division. World population prospects 2017 [internet]. New York: United Nations; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="https://esa.un.org/unpd/wpp/">https://esa.un.org/unpd/wpp/</ext-link> [cited 2019 Apr 8].</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Johnson</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Mossong</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dorrington</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Schomaker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hoffmann</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Keiser</surname>
<given-names>O</given-names></string-name>, <etal>et al.</etal>; <collab>International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration</collab>. <article-title>Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.</article-title>
<source>PLoS Med</source>. <year>2013</year>
<month>10</month>
<day>9</day>;<volume>10</volume>(<issue>4</issue>):<elocation-id>e1001418</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001418</pub-id><pub-id pub-id-type="pmid">23585736</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Bor</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Herbst</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Newell</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>B&#x000e4;rnighausen</surname>
<given-names>T</given-names></string-name>. <article-title>Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment.</article-title>
<source>Science</source>. <year>2013</year>
<month>2</month>
<day>22</day>;<volume>339</volume>(<issue>6122</issue>):<fpage>961</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1230413</pub-id><pub-id pub-id-type="pmid">23430655</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Price</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Glynn</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chihana</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kayuni</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Floyd</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Slaymaker</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Sustained 10-year gain in adult life expectancy following antiretroviral therapy roll-out in rural Malawi: July 2005 to June 2014.</article-title>
<source>Int J Epidemiol</source>. <year>2017</year>
<month>4</month>
<day>1</day>;<volume>46</volume>(<issue>2</issue>):<fpage>479</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28338707</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Gras</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kesselring</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Griffin</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>van Sighem</surname>
<given-names>AI</given-names></string-name>, <string-name><surname>Fraser</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Ghani</surname>
<given-names>AC</given-names></string-name>, <etal>et al.</etal>; <collab>ATHENA, Netherlands National Observational Cohort Study</collab>. <article-title>CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2007</year>
<month>6</month>
<day>1</day>;<volume>45</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e31804d685b</pub-id><pub-id pub-id-type="pmid">17414934</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Surie</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Borgdorff</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Cain</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Click</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>DeCock</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Yuen</surname>
<given-names>CM</given-names></string-name>. <article-title>Assessing the impact of antiretroviral therapy on tuberculosis notification rates among people with HIV: a descriptive analysis of 23 countries in sub-Saharan Africa, 2010&#x02013;2015.</article-title>
<source>BMC Infect Dis</source>. <year>2018</year>
<month>9</month>
<day>26</day>;<volume>18</volume>(<issue>1</issue>):<fpage>481</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-018-3387-z</pub-id><pub-id pub-id-type="pmid">30257667</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="book"><string-name><surname>Acemoglu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Robinson</surname>
<given-names>JA</given-names></string-name>. <chapter-title>An African success story: Botswana.</chapter-title> In: <string-name><surname>Rodrik</surname>
<given-names>D</given-names></string-name>, editor. <source>In search of prosperity: analytic narratives on economic growth.</source>
<publisher-loc>Princeton</publisher-loc>: <publisher-name>Princeton University Press</publisher-name>; <year>2003</year> pp. <fpage>80</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1515/9781400845897-006</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="web">AVERT [internet]. HIV and AIDS in east and southern Africa. Brighton: AVERT; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa">https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa</ext-link> [cited 2019 Apr 4].</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Nattrass</surname>
<given-names>N</given-names></string-name>. <article-title>AIDS and the Scientific Governance of Medicine in Post-Apartheid South Africa.</article-title>
<source>Afr Aff (Lond)</source>. <year>2008</year>
<month>4</month>;<volume>107</volume>(<issue>427</issue>):<fpage>157</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1093/afraf/adm087</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="web">Pre-exposure prophylaxis (PREP) for HIV prevention [internet]. Brighton: AVERT; 2018. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.avert.org/professionals/hiv-programming/prevention/pre-exposure-prophylaxis">https://www.avert.org/professionals/hiv-programming/prevention/pre-exposure-prophylaxis</ext-link> [cited 2019 Apr 23].</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Hermans</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Andrews</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Bekker</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>R</given-names></string-name>. <article-title>The mass miniature chest radiography programme in Cape Town, South Africa, 1948&#x02013;1994: the impact of active tuberculosis case finding.</article-title>
<source>S Afr Med J</source>. <year>2016</year>
<month>1</month>
<day>1</day>;<volume>106</volume>(<issue>12</issue>):<fpage>1263</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.7196/SAMJ.2017.v106i12.10744</pub-id><pub-id pub-id-type="pmid">27917775</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Chanda-Kapata</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kapata</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Masiye</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Maboshe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Klinkenberg</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Cobelens</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Health seeking behaviour among individuals with presumptive tuberculosis in Zambia.</article-title>
<source>PLoS One</source>. <year>2016</year>
<month>10</month>
<day>6</day>;<volume>11</volume>(<issue>10</issue>):<elocation-id>e0163975</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0163975</pub-id><pub-id pub-id-type="pmid">27711170</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Calligaro</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Zijenah</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Theron</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Buser</surname>
<given-names>V</given-names></string-name>, <string-name><surname>McNerney</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial.</article-title>
<source>Lancet Infect Dis</source>. <year>2017</year>
<season>Apr </season><day>1</day>;<volume>17</volume>(<issue>4</issue>):<fpage>441</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30384-X</pub-id><pub-id pub-id-type="pmid">28063795</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Scott</surname>
<given-names>L</given-names></string-name>, <string-name><surname>da Silva</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Boehme</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Gilpin</surname>
<given-names>CM</given-names></string-name>. <article-title>Diagnosis of opportunistic infections: HIV co-infections &#x02013; tuberculosis.</article-title>
<source>Curr Opin HIV AIDS</source>. <year>2017</year>
<month>3</month>
<day>1</day>;<volume>12</volume>(<issue>2</issue>):<fpage>129</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1097/COH.0000000000000345</pub-id><pub-id pub-id-type="pmid">28059955</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Thindwa</surname>
<given-names>D</given-names></string-name>, <string-name><surname>MacPherson</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Choko</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Khundi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sambakunsi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ngwira</surname>
<given-names>LG</given-names></string-name>, <etal>et al.</etal>
<article-title>Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.</article-title>
<source>Int J Tuberc Lung Dis</source>. <year>2018</year>
<month>3</month>
<day>1</day>;<volume>22</volume>(<issue>3</issue>):<fpage>273</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.17.0370</pub-id><pub-id pub-id-type="pmid">29471904</pub-id></mixed-citation></ref></ref-list></back></article>